Prelude Therapeutics Inc
1 day chart
Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. The Company’s product candidates include PRT1419, PRT2527, PRT3789, and PRT3645. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is a potent and highly selective CDK9 inhibitor. PRT2527 treatment demonstrated robust efficacy in both hematological malignancies and solid tumor models with MYC. PRT3645 is a next-generation CDK4/6 inhibitor. PRT3789 is an IV-administered SMARCA2 degrader. Its pipeline consists of multiple distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders.
Buy US stocks in Australia starting with PRLD. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PRLD
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.